Since ibrutinib failed to prevent kidney injury and exacerbated the fibrotic phenotype in the UUO model, we verified the ability of ibrutinib to modify outcomes in mice submitted to rhabdomyolysis, a cause of AKI at risk of subsequent CKD also displaying increased expression of Il1b and Nlrp311. Here, IL1B is linked to rhabdomyolysis.